We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Bladder Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Guru Sonpavde
Nov 26, 2020
To summarize, this is a cisplatin-ineligible patients, who 'may' also be platinum-ineligible. The options off-trial are as follows in the following order in my mind:
1. Carboplatin+Gemcitabine x 4-6 cycles -->avelumab maintenance (if stable or responding) per JAVELIN Bladder-100 trial (although this patient is 'felt' to be platinum, i.e. chemo-ineligible, there is no clear definition of this group. Transient predictable myelosuppression from chemotherapy is in many ways more feasible to mitigate and manage than a severe immune adverse event.
2. Pembrolizumab (or atezolizumab) as firstline therapy is reasonable under the umbrella of platinum-ineligibility. However, in my practice, I have used tumor PD-L1 IHC status to guide me if I am contemplating firstline pemro or atezo- i.e. if PD-L1 expression high, I am comfortable offering firstline pembro, and if PD-L1 is low, I prefer the JAVELIN Bladder-100 approach in #1 above (which demonstrated benefit regardless of PD-L1 status)..
Apr 18, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Guru Sonpavde
Nov 26, 2020
Apr 18, 2024
Pending Moderator approval.